Table 3 Correlations between the pretreatment AGR and the clinicopathological factors
AGR | |||
|---|---|---|---|
Low | High | p-value | |
Performance Status | |||
0 | 31 | 31 | |
1/2 | 3 | 1 | 0.614 |
Body Mass Index (kg/m2) | |||
>18.5 | 30 | 28 | |
≤18.5 | 4 | 4 | 1.000 |
Location of primary tumor | |||
Colon | 16 | 20 | |
Rectum | 18 | 12 | 0.228 |
Histological type | |||
Well, Moderately | 29 | 29 | |
Poorly, Mucinous | 5 | 3 | 0.710 |
Detection of unresectable tumor | |||
Synchronous | 22 | 24 | |
Metachronous | 12 | 8 | 0.428 |
The number of organs affected by metastasis | |||
One organ | 24 | 20 | |
More than one organ | 10 | 12 | 0.603 |
Pretreatment CEA (ng/ml) | |||
>5 | 5 | 5 | |
≤5 | 29 | 27 | 1.000 |
Pretreatment CA19-9 (U/ml) | |||
>37 | 18 | 12 | |
≤37 | 15 | 19 | 0.222 |
Cholinesterase (IU/l) | |||
>235 | 2 | 7 | |
≤235 | 8 | 5 | 0.099 |
Cholesterol (mg/dl) | |||
>200 | 5 | 12 | |
≤200 | 8 | 1 | 0.011 |
Molecular targeted therapy | |||
No | 23 | 14 | |
Yes | 11 | 18 | 0.082 |
Average relative dose intensity (%) | |||
median (range) | 89.2 (50–100) | 93.4 (64.3-100) | 0.380 |